BMY Earnings
Upcoming earnings date and last 8 quarters of EPS surprise.
Next Earnings
EPS Surprise — Last 8 Quarters
Quarterly Detail
| Quarter | Report Date | Est EPS | Actual EPS | Surprise % | Result |
|---|---|---|---|---|---|
| Q1 2026 | Apr 30, 2026 | 1.42 | 1.58 | +11.18% | Beat |
| Q4 2025 | Feb 5, 2026 | 1.20 | 1.26 | +4.57% | Beat |
| Q3 2025 | Oct 30, 2025 | 1.52 | 1.63 | +7.55% | Beat |
| Q2 2025 | Jul 31, 2025 | 1.10 | 1.46 | +32.60% | Beat |
| Q1 2025 | Apr 24, 2025 | 1.50 | 1.80 | +19.88% | Beat |
| Q4 2024 | Feb 6, 2025 | 1.47 | 1.67 | +13.80% | Beat |
| Q3 2024 | Oct 31, 2024 | 1.50 | 1.80 | +19.98% | Beat |
| Q2 2024 | Jul 26, 2024 | 1.63 | 2.07 | +27.37% | Beat |
Recent Guidance Mentions (8-K)
- Apr 30, 2026 · 8-K
ompany continues to expect total Worldwide Eliquis revenues to increase in 2026, when compared to 2025, consistent with the range shown in the table below. 2026 Eliquis Revenue Guidance 2026 WW Revenue Growth* 10% - 15% * Compared to 2025 Worldwide Eliquis revenues. The 2026 financial guidance provided excludes the impact of any potential future strategic acqu
View 8-K filing → - Apr 30, 2026 · 8-K
ns or licensing of third-party intellectual property rights, we may update this information from time to time on our website, www.bms.com , in the "Investors" section. Non-GAAP guidance assumes exchange rates as of the date noted. The financial guidance is subject to risks and uncertainties applicable to all forward-looking statements as described elsewhere in
View 8-K filing → - Apr 30, 2026 · 8-K
n 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, the company’s 2026 financial guidance, its business development and multi-year allocation strategy, anticipated developments in the company’s pipeline, expectations with respect to the company’s future market posit
View 8-K filing →
Data updated May 25, 2026 · source: Yahoo Finance via yfinance